Business news from Ukraine

TOP-30 counrturies exporters to Ukraine, January-November 2015

image001

Excluding the temporarily occupied territories of the Autonomous Republic of Crimea, the city of Sevastopol and part of the anti-terrorist operation zone.

KOLONIST WINEMAKING COMPANY PLANS TO INCREASE WINE OUTPUT BY 15-20% IN 2016

ODESA. Feb 16 (Interfax-Ukraine) – Kolonist winemaking company (Odesa region) plans to boost wine production by 15-20% in 2016, Kolonist executive director Volodymyr Holodynets has told reporters.

He said that in 2015, the company processed 240 tonnes of grapes (around 140,000 bottles of wine), and this year the company plans to process 250 tonnes of grapes (160,000-170,000 bottles).

This year Kolonist plans to make a first pilot batch of sparkling wine under the Biser trademark. It will have 5,000 bottles.

The company also plans to use some wine materials to produce balsamic vinegar. Holodynets said that it is impossible to forecast its production volume, as it will be ready in five or six years, and this segment is unique for Ukraine now.

Kolonist produces wine under the Kolonist trademark in Bolhrad district of Odesa region. The owner and founder of the company is Ivan Plachkov.

 

LUTSK CARDBOARD-PAPER MILL’S PRODUCTION 38% UP IN JAN

KYIV. Feb 16 (Interfax-Ukraine) – Lutsk cardboard-paper mill, part of the United Cardboard Company belonging to businessman Mykola Lobov, produced goods worth UAH 22.3 million in January 2016, which is 37.7% up year-over-year, according to the Ukrpapir association.

The association said that during this period the mill made 3,000 tonnes of various types of cardboard – 3% down year-over-year, including a rise of 18% in packaging cardboard output, to 2,870 tonnes.

The mill did not produce box cardboard in January (400 tonnes in January 2015) as well as roofing cardboard, while cover board production plunged by 58.3%, to 120 tonnes. The mill also did not produce pulp (80 tonnes in January 2015).

One more company in the sector under control of the United Cardboard Company – Poninkivsky Cardboard and Paper Mill – boosted production by 64% in January 2016, to almost UAH 28 million.

The mill more than doubled production of box board, to 3,370 tonnes, and corrugated cardboard packaging output rose by 15%, to 4.07 million square meters.

Paper production rose by 23.2% in January 2016, to 210 tonnes.

Lutsk cardboard-paper mill LLC was founded on the basis of assets of Lutsk cardboard-ruberoid mill in summer 2012.

The mill produces raw materials for corrugated board production (fluting and test liner), roofing, box and cover cardboard.

In 2015, the mill produced goods worth UAH 404.55 million, which was 67.1% up year-over-year.

Poninkivsky Cardboard and Paper Mill was founded over 200 years ago. The mill produces cardboard and paper.

In 2015, the mill saw a rise of 97.3% in production, to UAH 329.22 million.

BIOFARMA PLANS TO RESTORE REGULAR DONOR INSTITUTION TO RECEIVE BLOOD TO PRODUCE BLOOD PRODUCTS

KYIV. Feb 16 (Interfax-Ukraine) – Biofarma pharmaceutical company (Kyiv region) as part of the implementation of the project on reconstruction of the Sumy blood donor center plans to restore the regular donor institution to receive high-quality blood for production of blood products.

“Today we’re forming the regular donor institution… Mainly we need to receive high-quality blood components for hospitals and plasma for the fractionator plant. It’s not a secret that there is a high level of virus diseases in Ukraine, as HIV, hepatitis, including hepatitis C, tuberculosis,” Board Chairman Kostiantyn Yefymenko said in an interview with Interfax-Ukraine.

He also said that Biofarma started construction of a blood plasma fractionator with a projected capacity of 400 tonnes in 2015. In April 2016, the company plans to sign contracts to supply equipment for the plant.

“We’ve invested in the Sumy regional blood center to supply enough high-quality blood to the fractionator plant. It is being reconstructed by Biofarma in partnership with Sumy region. We’ve fully modernized the regional blood center. We actually removed everything old one and build a new center which today collects 3 tonnes of plasma a month and it is able to boost it to 5 tonnes,” he said.

Yefymenko said that the company plans to resume donor culture which was lost at many blood centers.

“Our task is to attract as many as possible regular donors who we’re confident of,” he said.

Yefymenko said that the Sumy blood donor center is one of few examples of the successful public private partnership. The Biofarma’s investment in the project reached around $3 million.

Biofarma is among the ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.

Niobera Investments Limited (Cyprus) holds 100% in Biofarma. According to the National Commission for Securities and the Stock Market of Ukraine, Biofarma Board Chairman Kostiantyn Yefymenko is the ultimate beneficiary of a large shareholder in Niobera Investments Limited. Shares do not belong to members of the executive body.

In 2014, Biofarma built a pharmaceutical plant in Bila Tserkva (Kyiv region). Investment totaled $42 million.

In 2014, Biofarma cut its net profit by 9.91% from a year ago, to UAH 25.801 million.

BIOFARMA PLANS TO RETAIN INVESTMENT AT $12 MLN IN 2016

KYIV. Feb 16 (Interfax-Ukraine) – Biofarma pharmaceutical company (Kyiv region) plans to retain investment in its development in 2016 at the level of 2015 – $12 million.

“In general, in 2015 our investment reached $12 million. We plan not the smaller sum for 2016,” Board Chairman Kostiantyn Yefymenko told Interfax-Ukraine.

He said that last year Biofarma invested $5 million in construction of a probiotic workshop, $3 million in reconstruction of the Sumy blood donor center and $2 million was invested in designing of new medicines.

In addition, Yefymenko said that in 2015 Biofarma renewed the marketing and sales service.

“Now persons with experience of work in famous international corporations are among our top managers. Today this is important as in 2015 we introduced some new medicines to the market and we’re preparing new forms of our products, including nasal sprays, eye drops and suppositories. Probiotics have been launched to the active promotion,” he said.

Yefymenko said that blood preparations are a top-priority direction for the company. In money terms revenue from their sales is 40%.

Biofarma is among the ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.

Niobera Investments Limited (Cyprus) holds 100% in Biofarma. According to the National Commission for Securities and the Stock Market of Ukraine, Biofarma Board Chairman Kostiantyn Yefymenko is the ultimate beneficiary of a large shareholder in Niobera Investments Limited. Shares do not belong to members of the executive body.

In 2014, Biofarma built a pharmaceutical plant in Bila Tserkva (Kyiv region). Investment totaled $42 million.

In 2014, Biofarma cut its net profit by 9.91% from a year ago, to UAH 25.801 million.

UCBU PROPOSES NBU TO DEVELOP PROGRAM FOR DEVELOPMENT, SUPPORT OF SMALL AND MEDIUM BANKS

KYIV. Feb 15 (Interfax-Ukraine) – The acceleration of the pace of increasing the minimum capital of banks will lead to the artificial withdrawal of small and medium-sized banks from the market, according to the Ukrainian Credit Banking Union (UCBU).

“The union believes that such actions of the National Bank of Ukraine (NBU) do not correspond to the current state of the economy as a whole, accelerate the artificial removal of small and medium-sized banks, which have been stably and transparently operating in Ukraine for many years, fulfill the National Bank’s economic regulations, have positive results of audits and other indicators confirming their reliability, from the market,” reads a press release from the UCBU.

According to the document, the NBU’s policy aimed at withdrawing a group of small and medium-sized banks from the market is contrary to the national interests of the country, international practice, as well as prevents the resumption of confidence in the banking system as a whole. Such policies should be discontinued and reoriented to the creation of proper conditions for the activity of small banks, which stably work in their own niche in the banking services market. According to the union, in modern conditions such banks require a separate program of support and development.